Pfizer is considering the sale of its women’s health portfolio as the drugmaker looks to focus on developing treatments with higher growth potential, according to Bloomberg sources.
The drugmaker is privately working with financial advisers to gauge interest from potential buyers. The division has annual sales of roughly $1.2 billion, and sources expect that a sale could yield about $2 billion.
Pfizer recently reported worse-than-expected third quarter revenue and lowered its full-year sales forecast as it struggles to deal with generic competition, manufacturing issues and drug pricing pressure in the United States.
Pfizer has not commented on the potential women’s health sale.
Read the Bloomberg coverage